Condition: Gastric Adenocarcinoma · Sponsor: Peking University Cancer Hospital & Institute
To evaluate the efficacy and safety of Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1 conversion therapy for initial unresectable local progression or potential resectable metastatic gastric adenocarcinoma.
This description comes directly from the study's public registry record.
Jiafu ji, MD · 86-010-88196048 · jiafuj@hotmail.com
Zhaode Bu, MD · 86-010-88196945 · buzhaode@cjcrcn.org
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04047953